Drug intelligence / Profile preview

AMP-03

Development stage: Preclinical
Lead developer: Reverb Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**AMP-03** is a bispecific antibody developed by Reverb Therapeutics using its proprietary Amplify R™ platform for the treatment of autoimmune disorders. It leverages bispecific antibody technology to engage multiple targets, potentially enhancing efficacy in modulating immune responses, though specific indications and mechanism details remain early-stage.[1]

Beyond the preview

Go deeper on AMP-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-03.

Explore the full profile